Up to 40% of dogs may have radiographic osteoarthritis - New long-acting monoclonal antibody therapy offers three months of osteoarthritis pain relief for dogs with a single injection
PARSIPPANY, N.J., July 15, 2026--(BUSINESS WIRE)--Zoetis Inc. (NYSE: ZTS) today announced that it has recently launched Lenivia® (izenivetmab injection) in Canada and the European Union (EU) member states – a new long-acting monoclonal antibody (mAb) therapy designed to deliver up to three months of osteoarthritis (OA) pain management with a single subcutaneous injection. Backed by a decade of science and research, Lenivia demonstrated a sustained reduction in pain in a pivotal nine-month European field study, with effects observed from as early as Day 7 after the first injection1. Lenivia targets nerve growth factor (NGF), a recognized mediator of pain and inflammation, and binds to a different site on NGF versus already commercialised anti-NGF mAbs.
Up to 40% of dogs may have radiographic osteoarthritis2,3, a chronic and progressive condition that can lower quality of life for dogs. OA pain erodes a dog's mobility, sleep, behavior and social relationships4. As dogs and cats live longer due to advances in veterinary care and nutrition, the number of senior pets is growing5,6. With age, conditions such as osteoarthritis become more common - highlighting the need for safe, effective long-term pain management options7,8. For millions of pet owners across Europe and Canada, the impact on their dogs' quality of life is impossible to ignore. Medications that are more convenient in delivering sustained pain control for this chronic disease fill an unmet need to achieve increased compliance with treatment.
A longer-acting option for a chronic condition
"Osteoarthritis affects millions of dogs across Europe and Canada, and for many pet owners, watching their companion struggle with pain, reduced mobility and lower quality of life is deeply personal," said Jamie Brannan, Executive Vice President and Chief Commercial Officer of Zoetis. "Our investment in long-acting monoclonal antibody therapies reflects Zoetis' commitment to addressing this unmet need with science-driven solutions that help veterinary professionals and pet owners keep dogs more comfortable as part of a broader, individualized management plan. A longer dosing interval can help free up capacity in the practice while offering pet owners greater convenience and improved compliance for the dog - which supports more consistent, long-term management of this chronic condition. We look forward to supporting veterinary professionals as the therapy becomes widely available."